https://www.pharmaradar360.com/article/intermountain-health-primary-children-s-hospital-to-host-mountain-west-stop-of-1-28fd0f50b408f3ecPharma Surgeen2026-07-24T14:35:39.000ZIntermountain Health Primary Children’s Hospital to Host Mountain West Stop of ‘100 Cleft Portraits’ Tour – Free National Traveling Art Exhibit Open to Publichttps://www.pharmaradar360.com/article/fda-warning-letters-highlight-contamination-control-and-facility-maintenance-fai-4edfd5d3386a63ddPharma Surgeen2026-07-24T14:14:36.000ZFDA warning letters highlight contamination control and facility maintenance failureshttps://www.pharmaradar360.com/article/republique-democratique-du-congo-8-tonnes-de-medicaments-acheminees-en-ituri-pou-ccf2374280ece631Pharma Surgeen2026-07-24T13:46:13.000ZRépublique démocratique du Congo : 8 tonnes de médicaments acheminées en Ituri pour soutenir la réponse à l'épidémie d'Ebolahttps://www.pharmaradar360.com/article/who-good-manufacturing-practices-for-pharmaceutical-products-main-principles-e3385484b0abc052Pharma Surgeen2026-07-24T13:46:03.000ZWHO good manufacturing practices for pharmaceutical products: Main principleshttps://www.pharmaradar360.com/article/legend-biotech-why-i-m-ready-to-go-long-again-nasdaq-legn-e012ab971e0b5ca9Pharma Surgeen2026-07-24T13:45:09.000ZLegend Biotech: Why I'm Ready To Go Long Again (NASDAQ:LEGN)https://www.pharmaradar360.com/article/ai-helps-stanford-scientists-discover-natural-ozempic-without-the-usual-side-eff-3398d67e3699e262Pharma Surgeen2026-07-24T13:44:43.000ZAI helps Stanford scientists discover “natural Ozempic” without the usual side effectshttps://www.pharmaradar360.com/article/medtronic-tells-remote-workers-living-near-the-twin-cities-to-come-back-to-the-o-a14c60dc4498c22cPharma Surgeen2026-07-24T13:43:23.000ZMedtronic tells remote workers living near the Twin Cities to come back to the officehttps://www.pharmaradar360.com/article/fatal-gene-editing-trial-in-china-raises-ethics-and-oversight-questions-9f5f96101c7e9d3aPharma Surgeen2026-07-24T13:43:06.000ZFatal gene-editing trial in China raises ethics and oversight questionshttps://www.pharmaradar360.com/article/minnesota-teen-cannabis-use-fell-sharply-but-some-groups-still-far-behind-u-of-m-06ca7a4f52b20584Pharma Surgeen2026-07-24T13:42:36.000ZMinnesota teen cannabis use fell sharply, but some groups still far behind, U of M study findshttps://www.pharmaradar360.com/article/gsk-s-first-lung-cancer-approval-a-new-ipo-path-and-more-fbfa0bdbceb47a7cPharma Surgeen2026-07-24T13:42:35.000ZGSK’s first lung cancer approval, a new IPO path and morehttps://www.pharmaradar360.com/article/minnesota-s-boreal-forest-won-t-survive-a-hotter-more-fiery-future-591452d80d6e3873Pharma Surgeen2026-07-24T13:42:06.000ZMinnesota’s boreal forest won’t survive a hotter, more fiery futurehttps://www.pharmaradar360.com/article/guidelines-on-goods-manufacturing-practices-who-a607f79b893edb13Pharma Surgeen2026-07-24T13:41:22.000ZGuidelines on Goods Manufacturing Practices(WHO)https://www.pharmaradar360.com/article/mobile-skin-clinic-expands-dermatologic-care-to-underserved-communities-of-minne-50ad9c87d6175fd3Pharma Surgeen2026-07-24T13:41:12.000ZMobile skin clinic expands dermatologic care to underserved communities of Minnesotahttps://www.pharmaradar360.com/article/beyond-deer-ticks-and-lyme-disease-rare-illnesses-and-tick-biodiversity-0da20cd5f032a368Pharma Surgeen2026-07-24T13:40:34.000ZBeyond deer ticks and Lyme disease: Rare illnesses and tick biodiversityhttps://www.pharmaradar360.com/article/u-studying-zoo-animal-samples-to-find-next-disease-fighting-therapy-c3c5c1b7aa3dd54bPharma Surgeen2026-07-24T13:39:49.000ZU studying zoo animal samples to find next disease-fighting therapyhttps://www.pharmaradar360.com/article/scientists-discover-a-compound-that-could-supercharge-aging-muscle-repair-fb0b6be9905f002cPharma Surgeen2026-07-24T13:37:50.000ZScientists discover a compound that could supercharge aging muscle repairhttps://www.pharmaradar360.com/article/guidelines-on-goods-manufacturing-practices-0aac2d8583cc8415Pharma Surgeen2026-07-24T13:32:57.000ZGuidelines on Goods Manufacturing Practiceshttps://www.pharmaradar360.com/article/fortrea-clinical-pharmacology-services-636c4c60b7129349Pharma Surgeen2026-07-24T13:27:39.000ZFortrea clinical pharmacology serviceshttps://www.pharmaradar360.com/article/a-new-antiviral-could-stop-measles-before-an-outbreak-takes-off-a8ae3ed8b737d8b8Pharma Surgeen2026-07-24T13:27:10.000ZA new antiviral could stop measles before an outbreak takes offhttps://www.pharmaradar360.com/article/si-no-57-of-2017-importation-and-exportation-296ddcba426133caPharma Surgeen2026-07-24T13:26:31.000ZSI-No-57-of-2017-Importation-and-Exportationhttps://www.pharmaradar360.com/article/guidelines-on-application-for-clinical-trial-authorisation-debf0b6bc444a48bPharma Surgeen2026-07-24T13:21:01.000ZGuidelines-on-Application for Clinical Trial Authorisationhttps://www.pharmaradar360.com/article/application-for-grant-of-marketing-authorisation-of-cosmetics-for-use-in-zambia-8471cfe2c03f5470Pharma Surgeen2026-07-24T13:17:30.000ZAPPLICATION-FOR-GRANT-OF-MARKETING-AUTHORISATION-OF-COSMETICS-FOR-USE-IN-ZAMBIAhttps://www.pharmaradar360.com/article/local-executives-to-spearhead-broward-heart-ball-campaign-focused-on-advancing-h-acedc7b644b4640dPharma Surgeen2026-07-24T13:16:00.000ZLocal executives to spearhead Broward Heart Ball campaign focused on advancing heart healthhttps://www.pharmaradar360.com/article/intermountain-health-plans-to-expand-ownership-of-hospitals-and-clinic-operation-b995a139e25950e2Pharma Surgeen2026-07-24T13:13:13.000ZIntermountain Health Plans to Expand Ownership of Hospitals and Clinic Operations Group in Southeast Idahohttps://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-net-asset-value-s-16e81f6701a394fcPharma Surgeen2026-07-24T13:06:00.000ZThe Biotech Growth Trust PLC - Net Asset Value(s)https://www.pharmaradar360.com/article/leeds-clinical-research-unit-cb1664e35a279e61Pharma Surgeen2026-07-24T13:05:24.000ZLeeds clinical research unithttps://www.pharmaradar360.com/article/peptide-l-wave-pcac-approves-four-bulk-drug-substances-for-the-503a-list-847ee4fa87405164Pharma Surgeen2026-07-24T13:04:38.000ZPEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A Listhttps://www.pharmaradar360.com/article/kolon-tissuegene-braces-for-100-mn-redemption-calls-on-convertible-bonds-adbca1daa4f87ad2Pharma Surgeen2026-07-24T13:04:19.000ZKolon TissueGene braces for $100 mn redemption calls on convertible bondshttps://www.pharmaradar360.com/article/munich-s-biotech-hub-inside-one-of-europe-s-leading-life-sciences-ecosystems-f34bb0d6f57ab6c0Pharma Surgeen2026-07-24T13:03:41.000ZMunich’s biotech hub: Inside one of Europe’s leading life sciences ecosystemshttps://www.pharmaradar360.com/article/fierce-pharma-asia-trump-s-generic-drug-tariffs-samsung-bio-s-1-8b-acquisition-a-ea8383574bbcca37Pharma Surgeen2026-07-24T13:00:00.000ZFierce Pharma Asia—Trump’s generic drug tariffs; Samsung Bio’s $1.8B acquisition; An unusual IPOhttps://www.pharmaradar360.com/article/biotech-etfs-xbi-and-pbe-diverge-sharply-in-str-2590435398ecca27Pharma Surgeen2026-07-24T12:41:56.000ZBiotech ETFs XBI and PBE diverge sharply in str...https://www.pharmaradar360.com/article/the-benefits-of-rapid-topline-pharmacokinetic-pk-data-in-clinical-pharmacology-s-dffff61a1ba38a31Pharma Surgeen2026-07-24T12:34:02.000ZThe benefits of rapid topline pharmacokinetic (PK) data in clinical pharmacology studieshttps://www.pharmaradar360.com/article/ridgetech-strengthens-pharmaceutical-ecosystem-leadership-with-vice-president-ro-5386dc072a2eecb6Pharma Surgeen2026-07-24T12:30:00.000ZRidgetech Strengthens Pharmaceutical Ecosystem Leadership with Vice-President Role in Zhejiang Biomedical Associationhttps://www.pharmaradar360.com/article/crispr-biotech-scribe-therapeutics-writes-a-new-chapter-with-129m-ipo-d17be9328e1dfc87Pharma Surgeen2026-07-24T12:23:17.000ZCRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPOhttps://www.pharmaradar360.com/article/earnings-call-transcript-bb-biotech-says-q2-portfolio-beat-sector-as-ai-push-adv-549175c1e789630aPharma Surgeen2026-07-24T12:16:35.000ZEarnings call transcript: BB Biotech says q2 portfolio beat sector as ai push advanceshttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-buy-on-lb-pharmaceuticals-stock-ec982c67189aaecdPharma Surgeen2026-07-24T12:16:00.000ZH.C. Wainwright reiterates Buy on LB Pharmaceuticals stockhttps://www.pharmaradar360.com/article/etf-showdown-xbi-vs-pbe-which-biotech-fund-wins-9195e9fb0866489ePharma Surgeen2026-07-24T12:15:52.000ZETF Showdown: XBI vs PBE, Which Biotech Fund Wins?https://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-5d5a454a6cf52b1cPharma Surgeen2026-07-24T12:11:26.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/west-pharmaceutical-delivers-another-beat-but-the-real-story-is-the-mix-shift-ny-75dd5edaeda2ec49Pharma Surgeen2026-07-24T12:08:48.000ZWest Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift (NYSE:WST)https://www.pharmaradar360.com/article/how-specialty-growth-and-cold-chain-demand-are-rewriting-distribution-strategy-89cbdd138b59bd85Pharma Surgeen2026-07-24T12:08:47.000ZHow Specialty Growth and Cold Chain Demand Are Rewriting Distribution Strategyhttps://www.pharmaradar360.com/article/bb-biotech-q2-2026-slides-nav-surges-17-12-new-investments-added-by-investing-co-6b98784ea4f22948Pharma Surgeen2026-07-24T12:02:17.000ZBB Biotech Q2 2026 slides: NAV surges 17%, 12 new investments added By Investing.comhttps://www.pharmaradar360.com/article/ruralrx-summer-interns-train-in-underserved-areas-083cb77c758e736fPharma Surgeen2026-07-24T12:00:12.000ZRuralRx summer interns train in underserved areashttps://www.pharmaradar360.com/article/jubilant-biosys-brings-together-global-biotech-leaders-to-advance-the-future-of-2ae1b2a03ca15e28Pharma Surgeen2026-07-24T12:00:00.000ZJubilant Biosys Brings Together Global Biotech Leaders to Advance the Future of Healthcare Innovation at 2nd EDGE Innovation Forumhttps://www.pharmaradar360.com/article/aspen-pharmacare-expands-access-ambitions-for-hiv-prevention-across-africa-throu-e3502bce3241926cPharma Surgeen2026-07-24T11:56:38.000ZAspen Pharmacare expands access ambitions for HIV prevention across Africa through new agreement with MSDhttps://www.pharmaradar360.com/article/bion-biotech-outperformance-fueled-by-m-a-clinical-progress-and-ai-driven-produc-d2b71eb5d8972d08Pharma Surgeen2026-07-24T11:46:53.000ZBION: Biotech outperformance fueled by M&A, clinical progress, and AI-driven productivity gainshttps://www.pharmaradar360.com/article/has-ocugen-s-recent-convertible-notes-offering-stabilized-its-financial-future-24b60403ee69b13dPharma Surgeen2026-07-24T11:39:37.000ZHas Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Futurehttps://www.pharmaradar360.com/article/einzigartige-fusion-fur-ki-gestutzte-prazisionsmedizin-44b81b6a9e85f43ePharma Surgeen2026-07-24T11:34:15.000ZEinzigartige Fusion für KI-gestützte Präzisionsmedizinhttps://www.pharmaradar360.com/article/the-billion-dollar-problem-keeping-ozempic-wegovy-and-zepbound-from-patients-94d8425eed5199c8Pharma Surgeen2026-07-24T11:29:04.000ZThe billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patientshttps://www.pharmaradar360.com/article/establishing-ctdna-as-a-validated-primary-surrogate-endpoint-c7d0ff5bb64441cfPharma Surgeen2026-07-24T11:28:18.000ZEstablishing ctDNA as a validated primary surrogate endpointhttps://www.pharmaradar360.com/article/dronare-med-hjartstartare-i-livraddande-insats-b697aaacab31a250Pharma Surgeen2026-07-24T11:22:09.000ZDrönare med hjärtstartare i livräddande insatshttps://www.pharmaradar360.com/article/q-a-brent-wilhelm-on-supply-chains-and-historical-demand-data-2c65ada0f2708714Pharma Surgeen2026-07-24T11:20:13.000ZQ&A : Brent Wilhelm on Supply Chains and Historical Demand Datahttps://www.pharmaradar360.com/article/strengthening-partnerships-visibility-and-sustainable-progress-in-the-cdmo-space-03e4e4a255b7a2c2Pharma Surgeen2026-07-24T11:02:21.000ZStrengthening partnerships, visibility and sustainable progress in the CDMO spacehttps://www.pharmaradar360.com/article/97-3f5257d8ec8092f4Pharma Surgeen2026-07-24T11:00:00.000Z「第97回 都市対抗野球大会」組み合わせ決定 日本新薬は鹿嶋市代表「日本製鉄鹿島」と対戦https://www.pharmaradar360.com/article/learning-support-fund-10th-edition-2026-to-2027-01ad8e4272fbaa77Pharma Surgeen2026-07-24T11:00:00.000ZLearning Support Fund 10th edition: 2026 to 2027https://www.pharmaradar360.com/article/learning-support-fund-guidance-eeb00075dd832df4Pharma Surgeen2026-07-24T11:00:00.000ZLearning Support Fund guidancehttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-jp-morgan-keeps-its-buy-rating-6c77dc41fba80d8ePharma Surgeen2026-07-24T10:57:22.000ZSARTORIUS STEDIM BIOTECH : JP Morgan keeps its Buy ratinghttps://www.pharmaradar360.com/article/clinicbarcelona-org-introduces-synth-voice-reading-for-content-and-automated-tra-07e586f7fd6044f2Pharma Surgeen2026-07-24T10:57:00.000ZClínicBarcelona.org introduces synth voice reading for content and automated transcription for videos and podcastshttps://www.pharmaradar360.com/article/why-playing-with-food-is-a-good-thing-b47cd1b49bb4038aPharma Surgeen2026-07-24T10:45:52.000ZWhy playing with food is a good thinghttps://www.pharmaradar360.com/article/merck-announces-initial-access-plans-for-alimatravir-an-investigational-once-mon-aba69ff2d2127a69Pharma Surgeen2026-07-24T10:45:00.000ZMerck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Developmenthttps://www.pharmaradar360.com/article/merck-announces-initial-access-plans-for-alimatravir-an-investigational-once-mon-37ff38f29e5048eePharma Surgeen2026-07-24T10:45:00.000ZMerck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Developmenthttps://www.pharmaradar360.com/article/merck-inks-landmark-generic-licensing-deal-for-monthly-hiv-pill-05846113f3fc7afbPharma Surgeen2026-07-24T10:45:00.000ZMerck Inks Landmark Generic Licensing Deal for Monthly HIV Pillhttps://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-de-uso-humano-de-julio-de-2026-8b85a535863e0192Pharma Surgeen2026-07-24T10:43:59.000ZReunión del Comité de Medicamentos de Uso Humano de julio de 2026https://www.pharmaradar360.com/article/polypid-azurity-sign-us-330m-deal-for-d-plex100-ddcae2910c7b75dfPharma Surgeen2026-07-24T10:41:15.000ZPolyPid, Azurity Sign US$330M Deal for D-PLEX100https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-26-july-2026-e8a5763a98861b0ePharma Surgeen2026-07-24T10:38:58.000ZWeekly all-cause mortality surveillance: week ending 26 July 2026https://www.pharmaradar360.com/article/requirements-for-the-listing-of-cosmetics-b50405c44df59aebPharma Surgeen2026-07-24T10:36:33.000ZREQUIREMENTS-FOR-THE-LISTING-OF-COSMETICShttps://www.pharmaradar360.com/article/gerresheimer-opens-new-pharmaceutical-glass-packaging-plant-in-china-7edee446fcaf83c8Pharma Surgeen2026-07-24T10:34:07.000ZGerresheimer opens new pharmaceutical glass packaging plant in Chinahttps://www.pharmaradar360.com/article/zamra-cosmetic-guidelines-22mar2023-v-lc-final-1-1c4c940d0275bcb2Pharma Surgeen2026-07-24T10:27:10.000ZZAMRA-Cosmetic-Guidelines-22Mar2023-v.LC-final-1https://www.pharmaradar360.com/article/reg-hikma-pharmaceutical-holding-s-in-company-3684898a71e64634Pharma Surgeen2026-07-24T10:25:35.000ZREG - Hikma Pharmaceutical - Holding(s) in Companyhttps://www.pharmaradar360.com/article/centennial-of-international-summer-school-at-universitat-heidelberg-a9b53b96595a4c71Pharma Surgeen2026-07-24T10:19:12.000ZCentennial of International Summer School at Universität Heidelberghttps://www.pharmaradar360.com/article/is-viking-therapeutics-poised-to-disrupt-the-weight-loss-market-afb5e819ae6f724ePharma Surgeen2026-07-24T10:18:22.000ZIs Viking Therapeutics Poised to Disrupt the Weight-Loss Markethttps://www.pharmaradar360.com/article/api-fpp-assessment-template-loq-v0-zazibona-26fb9f62dadf51adPharma Surgeen2026-07-24T10:16:27.000ZAPI FPP Assessment Template-LOQ_v0 – ZAZIBONAhttps://www.pharmaradar360.com/article/chmp-recommends-eu-approval-of-roche-s-susvimo-the-first-continuous-delivery-tre-2b2b158601dfddecPharma Surgeen2026-07-24T10:15:00.000ZCHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)https://www.pharmaradar360.com/article/active-biotech-doses-first-patient-in-updated-myelofibrosis-study-e7fd295f23d61b38Pharma Surgeen2026-07-24T10:14:40.000ZActive Biotech doses first patient in updated myelofibrosis studyhttps://www.pharmaradar360.com/article/chugai-pharmaceutical-chgcf-reports-strong-first-half-earnings-7fc2c1a3e01a1a96Pharma Surgeen2026-07-24T10:13:49.000ZChugai Pharmaceutical (CHGCF) Reports Strong First Half Earningshttps://www.pharmaradar360.com/article/roles-of-key-players-in-zazibona-process-v0-zazibona-280e83ad49c52b36Pharma Surgeen2026-07-24T10:12:36.000ZRoles of key players in Zazibona-process_v0 – ZAZIBONAhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-i-wst-stock-forecasts-d7cb4ee3f201fe14Pharma Surgeen2026-07-24T10:11:04.000ZWest Pharmaceutical Services, I (WST) Stock Forecastshttps://www.pharmaradar360.com/article/cabio-biotech-s-trading-to-halt-to-implement-risk-warning-67c05478ed8e17ddPharma Surgeen2026-07-24T09:59:19.000ZCabio Biotech's Trading To Halt To Implement Risk Warninghttps://www.pharmaradar360.com/article/active-wards-day-highlights-benefits-of-keeping-patients-moving-across-nhsggc-a899ce0f30e0f0f5Pharma Surgeen2026-07-24T09:54:18.000ZActive Wards Day highlights benefits of keeping patients moving across NHSGGChttps://www.pharmaradar360.com/article/healthcare-demand-upgrade-eps-creative-health-technology-group-3860-hk-expands-i-0a2260b0adfacf5fPharma Surgeen2026-07-24T09:48:16.000ZHealthcare Demand Upgrade, EPS Creative Health Technology Group (3860.HK) Expands Its Healthcare Businesshttps://www.pharmaradar360.com/article/moderne-behandlung-bei-ubergewicht-spritze-diat-oder-chirurgie-320f5510f53be392Pharma Surgeen2026-07-24T09:47:33.000ZModerne Behandlung bei Übergewicht – Spritze, Diät oder Chirurgie?https://www.pharmaradar360.com/article/edinburgh-athletes-on-the-world-stage-at-commonwealth-games-fae8727d9f790ef3Pharma Surgeen2026-07-24T09:39:00.000ZEdinburgh athletes on the world stage at Commonwealth Gameshttps://www.pharmaradar360.com/article/ubs-downgrades-legend-biotech-stock-rating-on-competition-concerns-802b9c5af9f6276dPharma Surgeen2026-07-24T09:36:55.000ZUBS downgrades Legend Biotech stock rating on competition concernshttps://www.pharmaradar360.com/article/neurocrine-bolsters-senior-ranks-as-it-builds-beyond-ingrezza-3dc6a1ed88e29632Pharma Surgeen2026-07-24T09:33:34.000ZNeurocrine bolsters senior ranks as it builds beyond Ingrezzahttps://www.pharmaradar360.com/article/fda-panel-narrowly-backs-two-peptides-for-compounding-list-cabd4df90f2e222bPharma Surgeen2026-07-24T09:33:34.000ZFDA panel narrowly backs two peptides for compounding listhttps://www.pharmaradar360.com/article/three-decades-at-the-aleksanteri-institute-hegel-and-soviet-philosophy-interview-c5a3766a823a8ce4Pharma Surgeen2026-07-24T09:31:52.000ZThree Decades at the Aleksanteri Institute, Hegel, and Soviet Philosophy: Interview with Professor Emeritus Vesa Oittinenhttps://www.pharmaradar360.com/article/why-radiopharmaceuticals-scientific-promise-meets-market-momentum-749b9408ca148308Pharma Surgeen2026-07-24T09:28:35.000ZWhy radiopharmaceuticals: Scientific promise meets market momentumhttps://www.pharmaradar360.com/article/ubs-downgrades-legend-biotech-stock-rating-on-competition-concerns-a1955f44b8566580Pharma Surgeen2026-07-24T09:21:00.000ZUBS downgrades Legend Biotech stock rating on competition concernshttps://www.pharmaradar360.com/article/biotech-stocks-consolidate-post-breakout-with-i-61ba6bdec3cdbcc4Pharma Surgeen2026-07-24T09:14:19.000ZBiotech stocks consolidate post-breakout with i...https://www.pharmaradar360.com/article/world-first-gene-therapy-treats-rare-form-of-childhood-blindness-b39f3e50ab5b1bdbPharma Surgeen2026-07-24T09:14:02.000ZWorld first gene therapy treats rare form of childhood blindnesshttps://www.pharmaradar360.com/article/sanofi-abandons-plan-to-seek-approval-for-eczema-drug-from-1-1b-kymab-buyout-6c04bd397c7b95e0Pharma Surgeen2026-07-24T09:13:10.000ZSanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyouthttps://www.pharmaradar360.com/article/bundibugyo-ebolavirus-why-the-2026-outbreak-is-a-medical-countermeasure-wake-up-08ae9ce801d17a3cPharma Surgeen2026-07-24T09:08:00.000ZBundibugyo Ebolavirus: Why the 2026 Outbreak Is a Medical Countermeasure Wake-Up Callhttps://www.pharmaradar360.com/article/big-pharma-s-patent-cliff-meets-a-new-biotech-cold-war-we-need-to-outrun-china-n-d5a74b2c5703436fPharma Surgeen2026-07-24T09:06:13.000ZBig pharma's patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw ithttps://www.pharmaradar360.com/article/guidelines-on-application-for-grant-of-marketing-authorisation-of-non-ivds-cb1507ce444dc205Pharma Surgeen2026-07-24T09:03:42.000ZGUIDELINES ON APPLICATION FOR GRANT OF MARKETING AUTHORISATION OF NON IVDShttps://www.pharmaradar360.com/article/guidelines-of-traceability-of-medicines-b25fc8bffb5eb9efPharma Surgeen2026-07-24T08:56:16.000ZGuidelines of Traceability of Medicineshttps://www.pharmaradar360.com/article/deutschlandstipendium-more-than-400-students-receive-certificates-9a4195543adc51b1Pharma Surgeen2026-07-24T08:53:42.000ZDeutschlandstipendium: more than 400 students receive certificateshttps://www.pharmaradar360.com/article/guidelines-on-recall-of-medicines-and-allied-substance-7694b07eabc95b8dPharma Surgeen2026-07-24T08:52:51.000ZGuidelines on Recall of Medicines and Allied Substancehttps://www.pharmaradar360.com/article/template-for-comments-on-guidelines-on-identification-and-labelling-of-medicines-683c9a7e29beae9cPharma Surgeen2026-07-24T08:49:57.000ZTemplate for comments on Guidelines on Identification and Labelling of Medicines and Allied Substances and Master Data Sharinghttps://www.pharmaradar360.com/article/guidelines-on-renewal-of-marketing-authorization-of-medicines-and-allied-substan-6995bc25ace3d2e2Pharma Surgeen2026-07-24T08:47:28.000ZGuidelines on Renewal of Marketing Authorization of Medicines and Allied Substances ZAMRA_2019v3https://www.pharmaradar360.com/article/the-spanish-cancer-association-joins-the-governing-board-of-the-clinic-barcelona-d45a4f72c13cd295Pharma Surgeen2026-07-24T08:45:00.000ZThe Spanish Cancer Association joins the Governing Board of the Clínic Barcelona Comprehensive Cancer Centrehttps://www.pharmaradar360.com/article/cspc-pharmaceutical-group-s-stock-price-soars-to-8-55-hkd-marking-a-robust-2-15-7bc9827d4239e2a7Pharma Surgeen2026-07-24T08:35:11.000ZCSPC Pharmaceutical Group's Stock Price Soars to 8.55 HKD, Marking a Robust 2.15% Increasehttps://www.pharmaradar360.com/article/essential-principles-of-safety-and-performance-of-medical-devices-v1-c44b0f61ead3061fPharma Surgeen2026-07-24T08:34:20.000ZEssential Principles of Safety and Performance of Medical Devices-v1https://www.pharmaradar360.com/article/the-u-s-pharmaceutical-supply-chain-problem-is-not-about-china-d5a7cc20885eaafdPharma Surgeen2026-07-24T08:33:20.000ZThe U.S. pharmaceutical supply chain problem is not about Chinahttps://www.pharmaradar360.com/article/chugai-pharmaceutical-co-ltd-2026-q2-results-earnings-call-presentation-otcmkts-b0dddc82e943ee96Pharma Surgeen2026-07-24T08:31:03.000ZChugai Pharmaceutical Co., Ltd. 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:CHGCY) 2026-07-24https://www.pharmaradar360.com/article/chugai-pharmaceutical-4519-q2-2026-earnings-summary-e4af80dd36982420Pharma Surgeen2026-07-24T08:11:11.000ZChugai Pharmaceutical (4519) Q2 2026 earnings summaryhttps://www.pharmaradar360.com/article/scribe-records-upsized-129m-ipo-to-bankroll-lipid-lowering-genetic-meds-80a02e9e9a6069a2Pharma Surgeen2026-07-24T08:00:00.000ZScribe records upsized $129M IPO to bankroll lipid-lowering genetic medshttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-shares-sold-by-atika-capital-management-8dfae341b134f493Pharma Surgeen2026-07-24T07:56:32.000ZTeva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Atika Capital Management LLChttps://www.pharmaradar360.com/article/data-centres-consume-vast-amounts-of-electricity-but-are-not-necessarily-the-mai-1a66edbe1bdc89c5Pharma Surgeen2026-07-24T07:50:39.000ZData centres consume vast amounts of electricity, but are not necessarily the main cause of grid peakshttps://www.pharmaradar360.com/article/bank-of-new-york-mellon-corp-decreases-stake-in-teva-pharmaceutical-industries-l-12cd97b61dd9881cPharma Surgeen2026-07-24T07:42:56.000ZBank of New York Mellon Corp Decreases Stake in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/almirall-builds-on-biologics-as-first-half-earnings-climb-f1126939070ce971Pharma Surgeen2026-07-24T07:33:20.000ZAlmirall builds on biologics as first-half earnings climbhttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-july-2026-5cb6f6902269e1ecPharma Surgeen2026-07-24T07:30:20.000ZUK Clinical Research Delivery key performance indicators: data to July 2026https://www.pharmaradar360.com/article/radiopharm-theranostics-raises-a-12-5-million-in-institutional-capital-as-rad101-c1892417a0a2dea3Pharma Surgeen2026-07-24T07:23:16.000ZRadiopharm Theranostics Raises A$12.5 Million in Institutional Capital as RAD101 Phase 3 Trial Nears Commencementhttps://www.pharmaradar360.com/article/chugai-pharmaceutical-first-half-fy2026-revenue-rose-14-7-and-core-net-income-in-9625b8bcdc7a7ba0Pharma Surgeen2026-07-24T07:11:41.000ZChugai Pharmaceutical : First-half FY2026 revenue rose 14.7% and core net income increased 23.2% year-over-yearhttps://www.pharmaradar360.com/article/celltrion-files-for-european-phase-3-trial-of-zymfentra-for-rheumatoid-arthritis-9229e1cc85b34d5ePharma Surgeen2026-07-24T07:03:25.000ZCelltrion Files for European Phase 3 Trial of Zymfentra for Rheumatoid Arthritishttps://www.pharmaradar360.com/article/ag-safety-and-health-center-at-unmc-welcomes-new-director-954ddc9b74d13809Pharma Surgeen2026-07-24T07:02:00.000ZAg safety and health center at UNMC welcomes new directorhttps://www.pharmaradar360.com/article/chugai-pharmaceutical-double-digit-revenue-and-profit-growth-driven-by-strong-sa-5039dc9a3b093416Pharma Surgeen2026-07-24T07:01:42.000ZChugai Pharmaceutical : Double-digit revenue and profit growth driven by strong sales and robust pipeline progresshttps://www.pharmaradar360.com/article/nominations-open-for-2027-impact-in-education-awards-9dd71d932f5eb7b0Pharma Surgeen2026-07-24T07:00:00.000ZNominations open for 2027 Impact in Education Awardshttps://www.pharmaradar360.com/article/2026-12-2-ecae905eb725624cPharma Surgeen2026-07-24T07:00:00.000Z2026年12月期第2四半期連結決算https://www.pharmaradar360.com/article/chugai-announces-2026-2nd-quarter-results-82a1c3e51e8371b3Pharma Surgeen2026-07-24T07:00:00.000ZChugai Announces 2026 2nd Quarter Resultshttps://www.pharmaradar360.com/article/unmc-achievements-july-24-2026-1777349af11ce10fPharma Surgeen2026-07-24T06:56:00.000ZUNMC achievements, July 24, 2026https://www.pharmaradar360.com/article/laminar-pharma-completes-lam561-phase-2b-3-trial-in-glioblastoma-935800571a205cdfPharma Surgeen2026-07-24T06:55:49.000ZLaminar Pharma Completes LAM561 Phase 2b/3 Trial in Glioblastomahttps://www.pharmaradar360.com/article/johnson-johnson-reports-positive-data-from-clinical-trial-of-bone-marrow-cancer-97f84818a765c5c2Pharma Surgeen2026-07-24T06:52:38.000ZJohnson & Johnson reports positive data from clinical trial of bone marrow cancer treatmenthttps://www.pharmaradar360.com/article/genmab-abbvie-clarify-epcoritamab-phase-3-trial-missed-primary-endpoint-1b7511dfd5b52370Pharma Surgeen2026-07-24T06:50:49.000ZGenmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpointhttps://www.pharmaradar360.com/article/embl-spin-off-epitome-therapeutics-launches-to-advance-precision-epigenome-editi-f4417d93db2222fbPharma Surgeen2026-07-24T06:42:35.000ZEMBL spin-off Epitome Therapeutics launches to advance precision epigenome editinghttps://www.pharmaradar360.com/article/gc-biopharma-files-phase-2-ind-for-covid-19-mrna-vaccine-candidate-8bf9939f9a67927fPharma Surgeen2026-07-24T06:14:02.000ZGC Biopharma files phase 2 IND for Covid-19 mRNA vaccine candidatehttps://www.pharmaradar360.com/article/bb-biotech-bion-q2-2026-earnings-summary-15750f4a9c5b7dfcPharma Surgeen2026-07-24T06:03:48.000ZBB Biotech (BION) Q2 2026 earnings summaryhttps://www.pharmaradar360.com/article/apoe2-may-protect-the-brain-from-alzheimer-s-and-aging-ac3bb520d00295c5Pharma Surgeen2026-07-24T06:00:15.000ZAPOE2 may protect the brain from Alzheimer’s and aginghttps://www.pharmaradar360.com/article/3-small-cap-biotech-stocks-pairing-rapid-revenue-growth-with-high-insider-owners-818a80177d2fa5ccPharma Surgeen2026-07-24T05:56:00.000Z3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownershiphttps://www.pharmaradar360.com/article/always-learn-philip-ashton-rickardt-on-building-a-biotech-career-without-a-bluep-cf11b68958bd9af6Pharma Surgeen2026-07-24T05:33:02.000ZAlways Learn: Philip Ashton-Rickardt on Building a Biotech Career Without a Blueprinthttps://www.pharmaradar360.com/article/32f0fca1766eb300Pharma Surgeen2026-07-24T05:28:17.000Z河北新報「気になる症状すっきり診断」に放射線診断科 科長 高瀬 圭教授の記事が掲載されましたhttps://www.pharmaradar360.com/article/dong-a-socio-to-absorb-pharmaceutical-unit-276242b0e6056801Pharma Surgeen2026-07-24T05:05:28.000ZDong-A Socio to absorb pharmaceutical unithttps://www.pharmaradar360.com/article/bb-biotech-reports-net-profit-of-chf-451-mln-in-q2-2026-72a2b6e2a7fbed1aPharma Surgeen2026-07-24T05:05:00.000ZBB Biotech Reports Net Profit Of CHF 451 Mln In Q2 2026https://www.pharmaradar360.com/article/bb-biotech-ag-publishes-its-interim-report-and-revises-its-dividend-policy-61e5234168771c3aPharma Surgeen2026-07-24T05:02:05.000ZBB Biotech AG publishes its interim report and revises its dividend policyhttps://www.pharmaradar360.com/article/bb-biotech-q2-2026-strong-nav-outperformance-driven-by-disciplined-stock-selecti-eefaa1181d29535aPharma Surgeen2026-07-24T05:01:04.000ZBB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioninghttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-2026-q2-results-earnings-call-presentation-nyse-8ac880f768453ee2Pharma Surgeen2026-07-24T05:00:48.000ZWest Pharmaceutical Services, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:WST) 2026-07-24https://www.pharmaradar360.com/article/bb-biotech-ag-publishes-its-interim-report-and-revises-its-dividend-policy-7219c6f89c92cb5cPharma Surgeen2026-07-24T05:00:00.000ZBB Biotech AG publishes its interim report and revises its dividend policyhttps://www.pharmaradar360.com/article/bb-biotech-q2-2026-strong-nav-outperformance-driven-by-disciplined-stock-selecti-33efaf16889cea83Pharma Surgeen2026-07-24T05:00:00.000ZBB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioninghttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-egyptian-international-pharmaceutical-indu-d9f212f49aa6f424Pharma Surgeen2026-07-24T04:59:28.000ZEnterprise value to EBITDA forward of Egyptian International Pharmaceutical Industries Co. – EGX:PHARhttps://www.pharmaradar360.com/article/hanmi-showcases-ai-platform-behind-clinical-stage-obesity-drug-at-ismb-cda65a17c854714dPharma Surgeen2026-07-24T04:59:07.000ZHanmi showcases AI platform behind clinical-stage obesity drug at ISMBhttps://www.pharmaradar360.com/article/news-analysis-kolon-faces-leadership-test-after-tg-c-s-first-us-phase-3-setback-6189a3d42c21d701Pharma Surgeen2026-07-24T04:54:06.000Z[News Analysis] Kolon faces leadership test after TG-C's first US phase 3 setbackhttps://www.pharmaradar360.com/article/stocks-to-watch-pharmaceutical-stocks-rose-supported-by-buying-in-defensive-name-3a247bfcb7a65378Pharma Surgeen2026-07-24T04:52:14.000Z〔Stocks to Watch〕Pharmaceutical stocks rose, supported by buying in defensive names and front-running purchases ahead of earnings announcements.https://www.pharmaradar360.com/article/world-pharmaceutical-grade-hyaluronic-acid-market-analysis-forecast-size-trends-f126202fe6c70774Pharma Surgeen2026-07-24T04:51:14.000ZWorld Pharmaceutical Grade Hyaluronic Acid - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-shenzhen-hepalink-pharmaceutical-group-co-lt-39a6292ff93ffd34Pharma Surgeen2026-07-24T04:51:01.000ZEnterprise value to EBIT forward of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A – SZSE:002399https://www.pharmaradar360.com/article/price-to-sales-forward-of-egyptian-international-pharmaceutical-industries-co-eg-62f835348487796ePharma Surgeen2026-07-24T04:42:41.000ZPrice to sales forward of Egyptian International Pharmaceutical Industries Co. – EGX:PHARhttps://www.pharmaradar360.com/article/cardiovascular-disease-biotech-scribe-therapeutics-prices-upsized-ipo-at-15-the-bc2696b3c0f316fePharma Surgeen2026-07-24T04:00:00.000ZCardiovascular disease biotech Scribe Therapeutics prices upsized IPO at $15, the high end of the rangehttps://www.pharmaradar360.com/article/codexis-announces-pricing-of-public-offering-of-common-stock-51c1e72335cb9e4aPharma Surgeen2026-07-24T03:47:00.000ZCodexis Announces Pricing of Public Offering of Common Stockhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-guizhou-bailing-group-pharmaceutical-co-ltd-class-a-9a1a58baa476e3c1Pharma Surgeen2026-07-24T03:41:18.000ZPrice to earnings forward of Guizhou Bailing Group Pharmaceutical Co., Ltd. Class A – SZSE:002424https://www.pharmaradar360.com/article/ozempic-and-mounjaro-linked-to-a-surprising-hair-loss-risk-2ffce34e5412e976Pharma Surgeen2026-07-24T03:31:13.000ZOzempic and Mounjaro linked to a surprising hair loss riskhttps://www.pharmaradar360.com/article/korea-europe-partner-on-ai-green-biotech-for-future-farming-e2341c5b5f6bd396Pharma Surgeen2026-07-24T03:28:00.000ZKorea, Europe partner on AI, green biotech for future farminghttps://www.pharmaradar360.com/article/fda-panel-recommends-loosening-restrictions-on-peptides-despite-scientists-conce-cc1cdb16df7c1d96Pharma Surgeen2026-07-24T03:04:00.000ZFDA panel recommends loosening restrictions on peptides, despite scientists’ concernshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-q2-earnings-call-highlights-60e2230a4c3db53cPharma Surgeen2026-07-24T03:04:00.000ZWest Pharmaceutical Services Q2 Earnings Call Highlightshttps://www.pharmaradar360.com/article/ibento-ibento-pmda-atc-blood-products-seminar-2026-for-ppwg-applications-open-27f70347c624c911Pharma Surgeen2026-07-24T03:00:00.000Z[IBENTO][IBENTO]PMDA-ATC Blood Products Seminar 2026 for PPWG Applications open.https://www.pharmaradar360.com/article/ibento-ibento-asean-japan-medical-devices-regulatory-seminar-2026-bec63d463a9cc88bPharma Surgeen2026-07-24T03:00:00.000Z[IBENTO][IBENTO]ASEAN-Japan Medical Devices Regulatory Seminar 2026https://www.pharmaradar360.com/article/ibento-ibento-pmda-atc-herbal-medicine-seminar-2026-473c29e17266db10Pharma Surgeen2026-07-24T03:00:00.000Z[IBENTO][IBENTO]PMDA-ATC Herbal Medicine Seminar 2026https://www.pharmaradar360.com/article/shinsa-considerations-for-the-clinical-evaluation-of-blood-coagulation-factor-vi-01c129eaa8bd1ee0Pharma Surgeen2026-07-24T03:00:00.000Z[SHINSA]Considerations for the Clinical Evaluation of Blood Coagulation Factor VIII and Factor IX Products for Pediatric Congenital Hemophilia (Early Consideration) posted.https://www.pharmaradar360.com/article/kokusai-the-8th-asian-network-meeting-anm-summary-has-been-posted-a8df75537166f666Pharma Surgeen2026-07-24T03:00:00.000Z[KOKUSAI]The 8th Asian Network Meeting (ANM) summary has been postedhttps://www.pharmaradar360.com/article/u-s-to-see-higher-generic-drug-prices-thanks-to-tariffs-ceo-of-leading-india-pha-6c979b5d8c2dd490Pharma Surgeen2026-07-24T02:24:00.000ZU.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warnshttps://www.pharmaradar360.com/article/dong-a-socio-holdings-to-absorb-dong-a-pharmaceutical-become-operating-holding-c-e08f64775a84c057Pharma Surgeen2026-07-24T02:18:10.000ZDong-A Socio Holdings to absorb Dong-A Pharmaceutical, become operating holding companyhttps://www.pharmaradar360.com/article/novocure-nvcr-breaks-out-on-q2-2026-earnings-optune-pax-driving-recovery-d29aa8bbd69d100aPharma Surgeen2026-07-24T02:02:41.000ZNovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recoveryhttps://www.pharmaradar360.com/article/gene-editor-scribe-therapeutics-starts-second-half-ipo-spree-with-129m-listing-6f2ba6f10ab00215Pharma Surgeen2026-07-24T02:01:00.000ZGene editor Scribe Therapeutics starts second-half IPO spree with $129M listinghttps://www.pharmaradar360.com/article/aluviones-y-remociones-en-masa-influyen-en-terremotos-y-volcanes-10dfce3fe1776cefPharma Surgeen2026-07-24T01:49:40.000ZAluviones y remociones en masa influyen en terremotos y volcaneshttps://www.pharmaradar360.com/article/scribe-secures-129m-in-a-rare-gene-editing-ipo-83ef5b880ea7bbd9Pharma Surgeen2026-07-24T01:30:06.000ZScribe secures $129M in a rare gene editing IPOhttps://www.pharmaradar360.com/article/arkbio-completes-all-cohort-dosing-in-australian-phase-i-trial-with-influenza-af-e547afb5c565c6a0Pharma Surgeen2026-07-24T01:29:22.000ZArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406https://www.pharmaradar360.com/article/china-s-biotech-innovation-fuels-merck-s-long-term-healthcare-bet-f2db53d542737b09Pharma Surgeen2026-07-24T01:15:32.000ZChina's biotech innovation fuels Merck's long-term healthcare bethttps://www.pharmaradar360.com/article/dimerix-secures-10-million-for-its-phase-3-kidney-trial-and-adds-a-new-asset-4d643a9daeb838e2Pharma Surgeen2026-07-24T01:14:00.000ZDimerix Secures $10 Million for Its Phase 3 Kidney Trial—and Adds a New Assethttps://www.pharmaradar360.com/article/multiple-logics-reshaping-china-s-pharmaceutical-industry-enters-a-critical-phas-29c52f599da84a7bPharma Surgeen2026-07-24T01:11:14.000ZMultiple Logics Reshaping: China's Pharmaceutical Industry Enters a Critical Phase of 'Strategic Stalemate'https://www.pharmaradar360.com/article/south-korea-accelerates-mrna-vaccine-push-as-gc-biopharma-seeks-phase-2-chosunbi-2560cd1abf7d3a9dPharma Surgeen2026-07-24T01:09:00.000ZSouth Korea accelerates mRNA vaccine push as GC Biopharma seeks phase 2 - CHOSUNBIZhttps://www.pharmaradar360.com/article/price-to-book-forward-of-nascent-biotech-inc-otc-nbio-74d2f15beebbd6f3Pharma Surgeen2026-07-24T01:01:17.000ZPrice to book forward of Nascent Biotech Inc. – OTC:NBIOhttps://www.pharmaradar360.com/article/arkbio-completes-all-cohort-dosing-in-australian-phase-i-trial-with-influenza-af-9f9c9389af90c3a3Pharma Surgeen2026-07-24T01:00:00.000ZArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406https://www.pharmaradar360.com/article/fda-panel-endorses-broader-use-of-certain-peptides-d5fcb2c6184bb614Pharma Surgeen2026-07-24T00:55:13.000ZFDA panel endorses broader use of certain peptideshttps://www.pharmaradar360.com/article/ct-enterprise-rebrands-as-cpbio-company-completes-transition-to-a-biotech-driven-ae9a1c511f34a2c3Pharma Surgeen2026-07-24T00:35:00.000ZCT ENTERPRISE Rebrands as CPBIO: Company completes transition to a biotech-driven business, positioning itself as an integrated life sciences platformhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-stock-up-3-4-but-gf-v-fbca6b588f4949e7Pharma Surgeen2026-07-24T00:33:45.000ZTeva Pharmaceutical Industries Ltd (TEVA) Stock Up 3.4% but GF Vhttps://www.pharmaradar360.com/article/krystal-biotech-inc-nasdaqgs-krys-added-to-s-p-400-biotechnology-741ccb8ec8b605dbPharma Surgeen2026-07-24T00:23:39.000ZKrystal Biotech, Inc.(NasdaqGS: KRYS) added to S&P 400 - Biotechnologyhttps://www.pharmaradar360.com/article/krystal-biotech-inc-nasdaqgs-krys-added-to-s-p-400-health-care-7d5a9acb719e54e9Pharma Surgeen2026-07-24T00:23:32.000ZKrystal Biotech, Inc.(NasdaqGS: KRYS) added to S&P 400 Health Carehttps://www.pharmaradar360.com/article/krystal-biotech-inc-nasdaqgs-krys-dropped-from-s-p-600-health-care-a74c831e6c79fdf2Pharma Surgeen2026-07-24T00:23:08.000ZKrystal Biotech, Inc.(NasdaqGS: KRYS) dropped from S&P 600 Health Carehttps://www.pharmaradar360.com/article/krystal-biotech-inc-nasdaqgs-krys-dropped-from-s-p-600-8516518ad722849ePharma Surgeen2026-07-24T00:22:59.000ZKrystal Biotech, Inc.(NasdaqGS: KRYS) dropped from S&P 600https://www.pharmaradar360.com/article/kolon-tissuegene-plunges-as-us-phase-3-fails-korea-investors-brace-for-fallout-c-cbe8f0d1b22aad70Pharma Surgeen2026-07-24T00:18:00.000ZKolon TissueGene plunges as US phase 3 fails; Korea investors brace for fallout - CHOSUNBIZhttps://www.pharmaradar360.com/article/boston-biotech-company-creates-perfumes-inspired-by-extinct-flowers-and-clouds-0de755f7c7d31967Pharma Surgeen2026-07-24T00:15:00.000ZBoston biotech company creates perfumes inspired by extinct flowers and cloudshttps://www.pharmaradar360.com/article/not-scientifically-supportable-inside-fda-s-refusal-to-face-us-generic-drug-cris-567e3d7874c31ad5Pharma Surgeen2026-07-24T00:07:00.000Z'Not scientifically supportable:' Inside FDA’s refusal to face US generic drug crisishttps://www.pharmaradar360.com/article/neuren-pharmaceuticals-advances-phase-3-koala-trial-for-phelan-mcdermid-syndrome-a589b19305c918e5Pharma Surgeen2026-07-24T00:06:18.000ZNeuren Pharmaceuticals Advances Phase 3 Koala Trial for Phelan-McDermid Syndrome as Presenting Sponsor of Family Conferencehttps://www.pharmaradar360.com/article/kdca-submits-phase-2-ind-for-domestic-mrna-covid-19-vaccine-4d5a09c34afb1b6dPharma Surgeen2026-07-24T00:03:03.000ZKDCA Submits Phase 2 IND for Domestic mRNA COVID-19 Vaccinehttps://www.pharmaradar360.com/article/safety-evaluation-of-certain-contaminants-in-food-prepared-by-the-one-hundred-an-18c0cbce73d64ac0Pharma Surgeen2026-07-24T00:00:00.000ZSafety evaluation of certain contaminants in food: prepared by the one hundred and first meeting of the...https://www.pharmaradar360.com/article/gsk-filed-form-6-k-5f94b9ff882f114aPharma Surgeen2026-07-24T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/2026-07-24-05-30-00-3332696-81c8579129d84d26Pharma Surgeen2026-07-24T00:00:00.000Z2026 07 24 05 30 00 3332696https://www.pharmaradar360.com/article/ai-based-clinician-decision-support-system-for-diagnosis-of-inherited-retinal-di-714640253ba48321Pharma Surgeen2026-07-24T00:00:00.000ZAI-based clinician decision support system for diagnosis of inherited retinal diseases: a multicenter, randomized trialhttps://www.pharmaradar360.com/article/prospective-validation-of-imaging-and-serum-diagnostic-biomarkers-of-steatohepat-6832be5da34245cdPharma Surgeen2026-07-24T00:00:00.000ZProspective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Studyhttps://www.pharmaradar360.com/article/briefing-chat-baby-t-rex-were-killers-from-birth-suggest-new-fossils-9a37447e6d9eb133Pharma Surgeen2026-07-24T00:00:00.000ZBriefing Chat: Baby T. rex were killers from birth, suggest new fossilshttps://www.pharmaradar360.com/article/personalized-gene-therapy-relieves-severe-epilepsy-in-two-boys-52c21d789ea1eba4Pharma Surgeen2026-07-24T00:00:00.000ZPersonalized gene therapy relieves severe epilepsy in two boyshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-f10ce9f887436584Pharma Surgeen2026-07-24T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-a624b99571276987Pharma Surgeen2026-07-24T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-3fa24f78dc61eb65Pharma Surgeen2026-07-24T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-e0605449c7ed9b2bPharma Surgeen2026-07-24T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-e8e599cd5f54127aPharma Surgeen2026-07-24T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-12aba7eab868ce90Pharma Surgeen2026-07-24T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-2a45c799886ecfa2Pharma Surgeen2026-07-24T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-a3c1e35b69ea6175Pharma Surgeen2026-07-24T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-ffedcdc25c48c60aPharma Surgeen2026-07-24T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-896ae89b16a77895Pharma Surgeen2026-07-24T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-17d14f7146ee87c9Pharma Surgeen2026-07-24T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-dd8bf244af827b9ePharma Surgeen2026-07-24T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-c2bb5f6213d6fcccPharma Surgeen2026-07-24T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-27b9c4104a97479ePharma Surgeen2026-07-24T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/view-latest-results-ec5f7049f7dae5acPharma Surgeen2026-07-24T00:00:00.000ZView latest resultshttps://www.pharmaradar360.com/article/chmp-recommends-gilead-s-trodelvy-plus-keytruda-in-pd-l-1-positive-first-line-me-fa733b6180d29000Pharma Surgeen2026-07-24T00:00:00.000ZCHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancerhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-2d10cd994e0d45e8Pharma Surgeen2026-07-24T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-9ae4bd0ea5a95af7Pharma Surgeen2026-07-24T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/hhs-request-for-comment-on-the-update-to-the-national-plan-to-address-alzheimer-63521a9fdf2dc075Pharma Surgeen2026-07-24T00:00:00.000ZHHS Request for Comment on the Update to the National Plan To Address Alzheimer's Diseasehttps://www.pharmaradar360.com/article/proposed-information-collection-activity-voluntary-acknowledgment-of-paternity-a-935368b113248b97Pharma Surgeen2026-07-24T00:00:00.000ZProposed Information Collection Activity; Voluntary Acknowledgment of Paternity and Required Data Elements for Paternity Establishment Affidavitshttps://www.pharmaradar360.com/article/evonik-corporation-filing-of-food-additive-petition-animal-use-2d73d2c3f28c70c7Pharma Surgeen2026-07-24T00:00:00.000ZEvonik Corporation, Filing of Food Additive Petition (Animal Use)https://www.pharmaradar360.com/article/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establis-5dbbee0d1f22d960Pharma Surgeen2026-07-24T00:00:00.000ZCellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvechttps://www.pharmaradar360.com/article/cellular-tissue-and-gene-therapies-advisory-committee-amendment-of-notice-biolog-74e65938a4fe9f54Pharma Surgeen2026-07-24T00:00:00.000ZCellular, Tissue, and Gene Therapies Advisory Committee; Amendment of Notice-Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells)https://www.pharmaradar360.com/article/rescinding-portions-of-the-u-s-department-of-health-and-human-services-title-vi-3aa038454e7059c3Pharma Surgeen2026-07-24T00:00:00.000ZRescinding Portions of the U.S. Department of Health and Human Services Title VI Regulations To Align With the Statutory Text and Conform to Executive Order 14281https://www.pharmaradar360.com/article/francis-esteban-matos-final-debarment-order-f26855201f352d58Pharma Surgeen2026-07-24T00:00:00.000ZFrancis Esteban Matos: Final Debarment Orderhttps://www.pharmaradar360.com/article/medical-devices-orthopedic-devices-classification-of-the-intraoperative-surgical-aff5100bb68f7c67Pharma Surgeen2026-07-24T00:00:00.000ZMedical Devices; Orthopedic Devices; Classification of the Intraoperative Surgical Angle Measurement Toolhttps://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-b63ccd511bcc8f65Pharma Surgeen2026-07-24T00:00:00.000ZMedical Devices; General Hospital and Personal Use Devices; Classification of the Diabetes Digital Behavioral Therapeutic Devicehttps://www.pharmaradar360.com/article/medical-devices-immunology-and-microbiology-devices-classification-of-the-over-t-70c5214d53bcd92ePharma Surgeen2026-07-24T00:00:00.000ZMedical Devices; Immunology and Microbiology Devices; Classification of the Over-the-Counter Test To Detect SARS-CoV-2 From Clinical Specimenshttps://www.pharmaradar360.com/article/medical-devices-clinical-chemistry-and-clinical-toxicology-devices-classificatio-4a5e704125dcac91Pharma Surgeen2026-07-24T00:00:00.000ZMedical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Prognostic Test for Assessment of Chronic Kidney Disease Progressionhttps://www.pharmaradar360.com/article/government-owned-invention-available-for-license-nucleophosmin-1-npm1-mutation-s-597e3f927de557d3Pharma Surgeen2026-07-24T00:00:00.000ZGovernment Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)https://www.pharmaradar360.com/article/government-owned-invention-available-for-license-pigment-epithelium-derived-fact-951aeede1e4fb031Pharma Surgeen2026-07-24T00:00:00.000ZGovernment Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degenerationhttps://www.pharmaradar360.com/article/government-owned-inventions-availability-for-licensing-07d033bcb11f37e3Pharma Surgeen2026-07-24T00:00:00.000ZGovernment-Owned Inventions; Availability for Licensinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meeting-e1af94bf43c527adPharma Surgeen2026-07-24T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/24-69-11-positive-list-smes-1c8be5f599307c20Pharma Surgeen2026-07-24T00:00:00.000Z24 ก.ค. 69อย. แท็กทีม 11 องค์กร คิกออฟ ยกระดับอาหารอนาคตไทย ผ่านระบบบัญชี Positive list หนุน SMEs แข่งขันระดับสากลอ่านเพิ่มเติม →https://www.pharmaradar360.com/article/24-69-ncds-b36fe5f7b12d25e5Pharma Surgeen2026-07-24T00:00:00.000Z24 ก.ค. 69อย. เดินหน้าขับเคลื่อน “ทางเลือกสุขภาพ” ติวเข้มผู้ประกอบการทั่วประเทศ มุ่งเพิ่มผลิตภัณฑ์สุขภาพ สร้างทางเลือกที่ดี ลดเสี่ยง NCDs อย่างยั่งยืนอ่านเพิ่มเติม →https://www.pharmaradar360.com/article/trixeo-recommended-for-approval-in-the-eu-by-chmp-for-the-maintenance-treatment-c31fda5a158d226dPharma Surgeen2026-07-24T00:00:00.000ZTrixeo recommended for approval in the EU by CHMP for the maintenance treatment of asthmahttps://www.pharmaradar360.com/article/enhertu-plus-pertuzumab-recommended-for-approval-in-the-eu-by-chmp-as-1st-line-t-c79bb0926b88d6d3Pharma Surgeen2026-07-24T00:00:00.000ZEnhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancerhttps://www.pharmaradar360.com/article/drug-label-update-aspercreme-professional-cream-d0e68a31047764a4Pharma Surgeen2026-07-24T00:00:00.000ZDrug label update: Aspercreme Professional Creamhttps://www.pharmaradar360.com/article/drug-label-update-penicillin-g-potassium-c242af57b15cc5b8Pharma Surgeen2026-07-24T00:00:00.000ZDrug label update: PENICILLIN G POTASSIUMhttps://www.pharmaradar360.com/article/tva-ki-forskare-far-innovationsfinansiering-fran-knut-och-alice-wallenbergs-stif-8a457ac764c74493Pharma Surgeen2026-07-24T00:00:00.000ZTvå KI-forskare får innovationsfinansiering från Knut och Alice Wallenbergs Stiftelsehttps://www.pharmaradar360.com/article/our-continued-commitment-to-the-hemophilia-b-community-an-update-on-hemgenix-etr-f6b12744c4ecc063Pharma Surgeen2026-07-24T00:00:00.000ZOur Continued Commitment to the Hemophilia B Community: An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Supply and Patient Accesshttps://www.pharmaradar360.com/article/effects-of-exercise-on-clinical-outcomes-in-patients-undergoing-haemodialysis-fo-47caf09969fbe57cPharma Surgeen2026-07-24T00:00:00.000ZEffects of exercise on clinical outcomes in patients undergoing haemodialysis for chronic kidney disease: an umbrella reviewhttps://www.pharmaradar360.com/article/do-moral-sensitivity-and-clinical-reasoning-differentiate-missed-nursing-care-a-76d0654a90949e85Pharma Surgeen2026-07-24T00:00:00.000ZDo moral sensitivity and clinical reasoning differentiate missed nursing care? A cross-sectional comparative studyhttps://www.pharmaradar360.com/article/airway-obstruction-a-comprehensive-literature-review-on-etiology-pathophysiology-6beceb897833dc02Pharma Surgeen2026-07-24T00:00:00.000ZAirway Obstruction: A Comprehensive Literature Review on Etiology, Pathophysiology, and Clinical Managementhttps://www.pharmaradar360.com/article/are-ai-models-ready-for-clinical-decision-making-in-dental-bleaching-an-evidence-90f1402798102fbcPharma Surgeen2026-07-24T00:00:00.000ZARE AI MODELS READY FOR CLINICAL DECISION-MAKING IN DENTAL BLEACHING? AN EVIDENCE-BASED EVALUATION OF ACCURACY, COMPLETENESS, AND READABILITY OF CHATGPT-5, GEMINI 2.5 PRO, DEEPSEEK V3.2, AND CLAUDE SONNET 4.5https://www.pharmaradar360.com/article/prognostic-significance-of-stem-cell-markers-in-triple-negative-breast-cancers-5543077e138735a6Pharma Surgeen2026-07-24T00:00:00.000ZPrognostic significance of stem cell markers: In triple-negative breast cancershttps://www.pharmaradar360.com/article/cross-sectional-survey-of-factors-influencing-treatment-adherence-in-elderly-can-1b8cfc514dc2b18cPharma Surgeen2026-07-24T00:00:00.000ZCross-sectional survey of factors influencing treatment adherence in elderly cancer patients in rural mountainous Guangyuan, Chinahttps://www.pharmaradar360.com/article/predictive-value-of-peripheral-blood-systemic-immune-inflammation-index-and-bloo-6334bb33041bc6f1Pharma Surgeen2026-07-24T00:00:00.000ZPredictive value of peripheral blood systemic immune-inflammation index and blood cell ratio for gastrointestinal polyp burden in patients with Peutz-Jeghers syndromehttps://www.pharmaradar360.com/article/letter-to-the-editor-beyond-cyst-size-a-time-risk-state-framework-for-dynamic-su-46630034a32a54cbPharma Surgeen2026-07-24T00:00:00.000ZLetter to the Editor: Beyond cyst size - a time-risk-state framework for dynamic surveillance de-escalation of branch duct intraductal papillary mucinous neoplasmshttps://www.pharmaradar360.com/article/multicenter-nomogram-integrating-clinicopathological-features-for-prognosis-in-s-00f95ee97dcac1b6Pharma Surgeen2026-07-24T00:00:00.000ZMulticenter nomogram integrating clinicopathological features for prognosis in stage II-III deficient/microsatellite instability-high rectal cancerhttps://www.pharmaradar360.com/article/metastasis-to-the-adrenal-glands-an-update-1c342ae391d72698Pharma Surgeen2026-07-24T00:00:00.000ZMetastasis to the adrenal glands: An updatehttps://www.pharmaradar360.com/article/harnessing-minimal-residual-disease-for-precision-medicine-in-locally-advanced-g-8445d72d01f197d5Pharma Surgeen2026-07-24T00:00:00.000ZHarnessing minimal residual disease for precision medicine in locally advanced gastric cancerhttps://www.pharmaradar360.com/article/multidimensional-mechanisms-of-drug-resistance-in-non-small-cell-lung-cancer-and-bfff4e2b25c30aa2Pharma Surgeen2026-07-24T00:00:00.000ZMultidimensional mechanisms of drug resistance in non-small cell lung cancer and novel strategies for overcoming ithttps://www.pharmaradar360.com/article/copper-homeostasis-imbalance-and-cuproptosis-emerging-targets-and-strategies-for-294fae5197491e37Pharma Surgeen2026-07-24T00:00:00.000ZCopper homeostasis imbalance and cuproptosis: Emerging targets and strategies for gastrointestinal tumor therapyhttps://www.pharmaradar360.com/article/determinants-of-magnetic-resonance-imaging-overstaging-in-rectal-cancer-t-stagin-3e6f713f6cbf0ccePharma Surgeen2026-07-24T00:00:00.000ZDeterminants of magnetic resonance imaging overstaging in rectal cancer T-staginghttps://www.pharmaradar360.com/article/whole-exome-sequencing-identification-of-the-risk-variants-in-a-middle-aged-adul-2ce2f3c5829e74cdPharma Surgeen2026-07-24T00:00:00.000ZWhole-exome sequencing identification of the risk variants in a middle-aged adult with intracranial Ewing’s sarcoma: A case reporthttps://www.pharmaradar360.com/article/letter-to-the-editor-cancer-stem-cell-and-oncomatrix-biomarkers-predict-chemothe-1ea035c2dff95134Pharma Surgeen2026-07-24T00:00:00.000ZLetter to the Editor: Cancer stem cell and oncomatrix biomarkers predict chemotherapy response and survival in triple-negative breast cancerhttps://www.pharmaradar360.com/article/letter-to-the-editor-patient-reported-outcomes-of-intensity-modulated-radiothera-5c859dd53d203922Pharma Surgeen2026-07-24T00:00:00.000ZLetter to the Editor: Patient-reported outcomes of intensity-modulated radiotherapy <i>vs</i> three-dimensional conformal radiotherapy in prostate cancerhttps://www.pharmaradar360.com/article/emergence-of-human-epidermal-growth-factor-receptor-2-as-a-key-biomarker-and-the-0923b93d6b424ddfPharma Surgeen2026-07-24T00:00:00.000ZEmergence of human epidermal growth factor receptor 2 as a key biomarker and therapeutic target in advanced urothelial carcinomahttps://www.pharmaradar360.com/article/profile-of-antidepressant-use-and-drug-interactions-among-psychiatric-outpatient-348df566913b334ePharma Surgeen2026-07-24T00:00:00.000ZProfile of Antidepressant Use and Drug Interactions among Psychiatric Outpatients at RSUD Ainun Habibiehttps://www.pharmaradar360.com/article/clinical-and-voice-related-characteristics-of-teachers-presenting-with-voice-dis-790b2675ee51f233Pharma Surgeen2026-07-24T00:00:00.000ZClinical and Voice-Related Characteristics of Teachers Presenting with Voice Disorders in Georgiahttps://www.pharmaradar360.com/article/amyand-s-hernia-with-necrotic-appendiceal-tip-successfully-managed-by-appendecto-f8ed5e424156d654Pharma Surgeen2026-07-24T00:00:00.000ZAmyand's Hernia with Necrotic Appendiceal Tip Successfully Managed by Appendectomy and Lichtenstein Mesh Repair: A Case Report and Literature Reviewhttps://www.pharmaradar360.com/article/topical-retinoids-versus-benzoyl-peroxide-in-acne-maintenance-therapy-comparativ-536519f36ff2abf6Pharma Surgeen2026-07-24T00:00:00.000ZTopical Retinoids Versus Benzoyl Peroxide in Acne Maintenance Therapy: Comparative Role, Evidence, And Practical Usehttps://www.pharmaradar360.com/article/adapalene-benzoyl-peroxide-versus-retinoid-monotherapy-for-acne-maintenance-evid-7390a313cb861a7ePharma Surgeen2026-07-24T00:00:00.000ZAdapalene/Benzoyl Peroxide Versus Retinoid Monotherapy for Acne Maintenance: Evidence, Relapse Prevention, And Practical Selectionhttps://www.pharmaradar360.com/article/ballantyne-syndrome-maternal-mirror-of-fetal-hydrops-diagnostic-challenges-and-c-ed8e64dae8b6b0f0Pharma Surgeen2026-07-24T00:00:00.000ZBallantyne Syndrome: Maternal Mirror of Fetal Hydrops, Diagnostic Challenges, And Contemporary Managementhttps://www.pharmaradar360.com/article/ashwagandha-supplementation-in-healthy-aging-and-musculoskeletal-health-biologic-ae57deb61a1eab6cPharma Surgeen2026-07-24T00:00:00.000ZAshwagandha Supplementation in Healthy Aging and Musculoskeletal Health: Biological Rationale, Clinical Evidence, and Safety Considerationshttps://www.pharmaradar360.com/article/subvastus-versus-medial-parapatelar-approach-in-primary-knee-arthroplasty-postop-d5e7ac2e097f21f1Pharma Surgeen2026-07-24T00:00:00.000ZSubvastus Versus Medial Parapatelar Approach in Primary Knee Arthroplasty: Postoperative Pain and Early Functionhttps://www.pharmaradar360.com/article/clinical-significance-of-age-and-coexisting-lifestyle-related-diseases-in-ild-pa-6943142fce5571c9Pharma Surgeen2026-07-24T00:00:00.000ZClinical Significance of Age and Coexisting Lifestyle-related Diseases in ILD Patients with Acute Exacerbationhttps://www.pharmaradar360.com/article/psychometric-validity-and-clinical-utility-of-the-ghq-12-for-screening-psycholog-886e10b0feecc0a3Pharma Surgeen2026-07-24T00:00:00.000ZPsychometric validity and clinical utility of the GHQ-12 for screening psychological health in isolated, confined and unusual or extreme environmentshttps://www.pharmaradar360.com/article/implementation-of-spirometry-telemonitoring-programme-in-lung-transplant-recipie-ccd814421fe1c374Pharma Surgeen2026-07-24T00:00:00.000ZImplementation of Spirometry Telemonitoring Programme in Lung Transplant Recipients: A Retrospective, Controlled Analysis of Clinical Outcomeshttps://www.pharmaradar360.com/article/off-hours-robotic-assisted-spine-instrumentation-in-a-teaching-hospital-feasibil-6834fe16d7faa216Pharma Surgeen2026-07-24T00:00:00.000ZOff-Hours Robotic-Assisted Spine Instrumentation in a Teaching Hospital: Feasibility Under Increased Emergency and Workflow Burdenhttps://www.pharmaradar360.com/article/neuron-specific-enolase-for-neurological-prognostication-after-cardiac-arrest-in-d434b5a0b618808ePharma Surgeen2026-07-24T00:00:00.000ZNeuron-Specific Enolase for Neurological Prognostication After Cardiac Arrest in the Era of Targeted Temperature Management: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/evaluation-of-intraocular-lens-power-calculation-formulas-for-highly-myopic-eyes-7f7925f220e4f4c0Pharma Surgeen2026-07-24T00:00:00.000ZEvaluation of Intraocular Lens Power Calculation Formulas for Highly Myopic Eyes: A Systematic Review and Network Meta-Analysishttps://www.pharmaradar360.com/article/strong-family-level-clustering-of-adolescent-weight-status-despite-limited-assoc-3f03e746e06d58a9Pharma Surgeen2026-07-24T00:00:00.000ZStrong Family-Level Clustering of Adolescent Weight Status Despite Limited Associations with Individual Parental Anthropometric and Metabolic Characteristicshttps://www.pharmaradar360.com/article/the-acid-base-effects-of-albumin-in-sepsis-reconciling-the-stewart-physicochemic-9317b4f0ad88b4cbPharma Surgeen2026-07-24T00:00:00.000ZThe Acid–Base Effects of Albumin in Sepsis: Reconciling the Stewart Physicochemical Approach with the Traditional Buffer–Base Paradigmhttps://www.pharmaradar360.com/article/serum-urate-as-a-cardiometabolic-risk-enhancer-beyond-score2-in-psoriatic-arthri-ba2d9cc2ca6054fcPharma Surgeen2026-07-24T00:00:00.000ZSerum Urate as a Cardiometabolic Risk Enhancer Beyond SCORE2 in Psoriatic Arthritishttps://www.pharmaradar360.com/article/treatment-of-typical-and-atypical-trigeminal-neuralgia-with-linac-based-radiosur-9596e01e087b7f6cPharma Surgeen2026-07-24T00:00:00.000ZTreatment of Typical and Atypical Trigeminal Neuralgia with LINAC-Based Radiosurgery: Complications, Recurrence Rates and Long-Term Treatment Outcomeshttps://www.pharmaradar360.com/article/predicting-pathological-complete-response-in-rectal-cancer-external-validation-o-d96d5a2e34ed52c3Pharma Surgeen2026-07-24T00:00:00.000ZPredicting Pathological Complete Response in Rectal Cancer: External Validation of Clinical Modelshttps://www.pharmaradar360.com/article/correction-huang-et-al-non-coding-rna-dual-effects-on-breast-cancer-metastasis-a-2129ae3488329bd5Pharma Surgeen2026-07-24T00:00:00.000ZCorrection: Huang et al. Non-Coding RNA: Dual Effects on Breast Cancer Metastasis and Clinical Applications. Cancers 2019, 11, 1802https://www.pharmaradar360.com/article/nanocarrier-based-drug-delivery-systems-for-lung-cancer-a-systematic-review-and-dd9bb9fe49534030Pharma Surgeen2026-07-24T00:00:00.000ZNanocarrier-Based Drug Delivery Systems for Lung Cancer: A Systematic Review and Meta-Analysis of Preclinical Studieshttps://www.pharmaradar360.com/article/from-randomised-trial-to-national-implementation-employment-outcomes-from-indivi-324364de5159d7c1Pharma Surgeen2026-07-24T00:00:00.000ZFrom randomised trial to national implementation: employment outcomes from individual placement and support in english alcohol and drug treatment serviceshttps://www.pharmaradar360.com/article/factors-associated-with-clinical-severity-in-scorpion-envenomation-a-retrospecti-dd7c3000139c83e0Pharma Surgeen2026-07-24T00:00:00.000ZFactors associated with clinical severity in scorpion envenomation: a retrospective cross-sectional study in western Mexico between 2021 and 2025https://www.pharmaradar360.com/article/embitterment-symptoms-and-comorbid-psychopathology-in-an-anxiety-outpatient-clin-e500f3fd8652bdf6Pharma Surgeen2026-07-24T00:00:00.000ZEmbitterment symptoms and comorbid psychopathology in an anxiety outpatient clinic: frequency, clinical distribution, and psychosocial correlateshttps://www.pharmaradar360.com/article/from-dual-inhibition-to-precision-selectivity-the-molecular-rationale-and-clinic-ca1f11989e7bebc6Pharma Surgeen2026-07-24T00:00:00.000ZFrom dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumorshttps://www.pharmaradar360.com/article/initial-clinical-experience-with-total-mullerian-compartment-resection-for-local-8d8754a05ae878ebPharma Surgeen2026-07-24T00:00:00.000ZInitial clinical experience with total Müllerian compartment resection for locally advanced cervical cancer: a single-center preliminary retrospective cohort study and learning-curve analysishttps://www.pharmaradar360.com/article/pretreatment-creatinine-to-cystatin-c-ratio-as-a-prognostic-marker-in-digestive-9d5811c8f559274bPharma Surgeen2026-07-24T00:00:00.000ZPretreatment creatinine-to-cystatin c ratio as a prognostic marker in digestive tract cancers: a meta-analysis with reconstructed individual patient data and trial sequential analysishttps://www.pharmaradar360.com/article/the-clinical-value-of-vhit-saccadic-parameters-in-the-diagnosis-and-management-o-81bc3c09bbc042caPharma Surgeen2026-07-24T00:00:00.000ZThe clinical value of vHIT saccadic parameters in the diagnosis and management of central vestibular disorders: a narrative reviewhttps://www.pharmaradar360.com/article/whole-genome-sequencing-and-molecular-analysis-of-carbapenem-resistant-escherich-7bf77af79e71c489Pharma Surgeen2026-07-24T00:00:00.000ZWhole-genome sequencing and molecular analysis of carbapenem-resistant Escherichia coli from clinical samples collected in the framework of the EURGen-Net CCRE survey, Italy 2019https://www.pharmaradar360.com/article/a-multifactorial-approach-to-tacrolimus-therapeutic-drug-monitoring-in-complex-l-deabee3ced3999fdPharma Surgeen2026-07-24T00:00:00.000ZA multifactorial approach to tacrolimus therapeutic drug monitoring in complex liver transplantation: a case reporthttps://www.pharmaradar360.com/article/cd19-car-t-cell-therapy-in-large-b-cell-lymphoma-clinical-evidence-resistance-to-eb0c243224c4e4edPharma Surgeen2026-07-24T00:00:00.000ZCD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategieshttps://www.pharmaradar360.com/article/ct-guided-intratumoral-immunotherapy-for-advanced-solid-tumors-a-prospective-cli-09b8fa102f5f5d63Pharma Surgeen2026-07-24T00:00:00.000ZCT-guided intratumoral immunotherapy for advanced solid tumors: a prospective clinical study of safety and systemic antitumor effectshttps://www.pharmaradar360.com/article/minireview-kefir-as-a-source-of-antimicrobial-compounds-against-bacterial-pathog-948fce0973034f53Pharma Surgeen2026-07-24T00:00:00.000ZMinireview Kefir as a source of antimicrobial compounds against bacterial pathogenshttps://www.pharmaradar360.com/article/clinical-relevance-of-circulating-endocan-and-endoglin-in-excess-body-weight-ass-ebb690b094adb611Pharma Surgeen2026-07-24T00:00:00.000ZClinical relevance of circulating endocan and endoglin in excess body weight-associated endothelial dysfunctionhttps://www.pharmaradar360.com/article/study-on-rheumatoid-arthritis-prediction-model-with-machine-learning-and-ensembl-6ac4569922dfa800Pharma Surgeen2026-07-24T00:00:00.000ZStudy on Rheumatoid Arthritis Prediction Model With Machine Learning and Ensemble Learning Methods, and Demographic, Clinical, Laboratory Characteristics of These Patientshttps://www.pharmaradar360.com/article/vagus-nerve-stimulation-in-drug-resistant-epilepsy-surgical-technique-from-a-ter-e55b22aab254dda7Pharma Surgeen2026-07-24T00:00:00.000ZVagus nerve stimulation in drug-resistant epilepsy: Surgical technique from a tertiary epilepsy centerhttps://www.pharmaradar360.com/article/the-nigerian-association-of-foreign-trained-pharmacists-strategic-framework-cham-71128f6b6175e1d3Pharma Surgeen2026-07-24T00:00:00.000ZThe Nigerian Association of Foreign Trained Pharmacists strategic framework: Championing the intersection of healthcare, public health and community servicehttps://www.pharmaradar360.com/article/coproduccion-de-tecnologias-y-derechos-no-reproductivos-activismo-feminista-sabe-312eebf75e3ca58ePharma Surgeen2026-07-24T00:00:00.000ZCoproducción de tecnologías y derechos no reproductivos: activismo feminista, saberes clínicos y construcción del misoprostol como droga abortivahttps://www.pharmaradar360.com/article/effects-of-platelet-lysate-on-the-rate-of-orthodontic-tooth-movement-a-single-ce-62327f4a5257af16Pharma Surgeen2026-07-24T00:00:00.000ZEffects of platelet lysate on the rate of orthodontic tooth movement: a single-center, split-mouth, randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-comparison-of-different-debonding-techniques-of-clear-aligner-attachmen-25239f91748d5decPharma Surgeen2026-07-24T00:00:00.000ZClinical comparison of different debonding techniques of clear aligner attachments: a single-center, split-mouth randomized clinical trialhttps://www.pharmaradar360.com/article/the-lens-that-lost-its-lustre-clinical-insights-from-five-cases-of-pciol-opacifi-af2def789de4b953Pharma Surgeen2026-07-24T00:00:00.000ZThe Lens That Lost Its Lustre: Clinical Insights from Five Cases of PCIOL Opacificationhttps://www.pharmaradar360.com/article/does-political-alignment-deliver-justice-sc-rape-reporting-conviction-and-trial-067710adfb1fd994Pharma Surgeen2026-07-24T00:00:00.000ZDoes Political Alignment Deliver Justice? SC Rape Reporting, Conviction, and Trial Pendency Under Partisan Alignment in India, 2001–2022https://www.pharmaradar360.com/article/therapeutic-inertia-in-pharmacologic-dose-optimization-prevalence-clinical-conse-e6e328ef37419ab7Pharma Surgeen2026-07-24T00:00:00.000ZTherapeutic Inertia in Pharmacologic Dose Optimization: Prevalence, Clinical Consequences, and Economic Burden Across Sixteen Chronic Conditionshttps://www.pharmaradar360.com/article/impact-of-tnf-alpha-308-g-a-polymorphism-on-response-to-tnf-inhibitors-in-tunisi-46dfb349942b8effPharma Surgeen2026-07-24T00:00:00.000ZImpact of TNF-alpha -308 G/A polymorphism on response to TNF inhibitors in Tunisian patients with inflammatory rheumatic diseaseshttps://www.pharmaradar360.com/article/qhbsag-trajectories-with-peg-ifn-2b-add-on-therapy-in-nucleos-t-ide-analog-exper-5507b945508d5cfePharma Surgeen2026-07-24T00:00:00.000ZqHBsAg Trajectories with Peg-IFNα-2b Add-on Therapy in Nucleos(t)ide Analog-experienced HBeAg-positive Chronic Hepatitis Bhttps://www.pharmaradar360.com/article/clinical-factors-related-to-cardiac-conduction-disturbance-in-patients-with-wild-1960f220eca28d40Pharma Surgeen2026-07-24T00:00:00.000ZClinical Factors Related to Cardiac Conduction Disturbance in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Undergoing Tafamidis Treatmenthttps://www.pharmaradar360.com/article/beyond-strut-coverage-toward-functional-endothelization-after-drug-eluting-stent-6c917b5b363406d7Pharma Surgeen2026-07-24T00:00:00.000ZBeyond Strut Coverage ― Toward Functional Endothelization After Drug-Eluting Stent Implantation ―https://www.pharmaradar360.com/article/clinical-outcomes-after-drug-eluting-stent-thrombosis-in-patients-on-hemodialysi-7bb001e7fe7e3fd6Pharma Surgeen2026-07-24T00:00:00.000ZClinical Outcomes After Drug-Eluting Stent Thrombosis in Patients on Hemodialysis ― Insights From the REAL-ST Registry ―https://www.pharmaradar360.com/article/assessment-of-and-factors-contributing-to-adequate-endothelization-after-drug-el-6cee74832917826ePharma Surgeen2026-07-24T00:00:00.000ZAssessment of and Factors Contributing to Adequate Endothelization After Drug-Eluting Stent Implantationhttps://www.pharmaradar360.com/article/aspirin-vs-clopidogrel-monotherapy-beyond-1-month-after-percutaneous-coronary-in-52b0c47c18c75d34Pharma Surgeen2026-07-24T00:00:00.000ZAspirin vs. Clopidogrel Monotherapy Beyond 1 Month After Percutaneous Coronary Intervention in Patients With Diabetes ― Prespecified Subgroup Analysis of the STOPDAPT-3 Trial ―https://www.pharmaradar360.com/article/a-phenylbutyrate-derived-nitric-oxide-donor-induces-pancreatic-cancer-cell-death-2f5e8a07ae4649ffPharma Surgeen2026-07-24T00:00:00.000ZA Phenylbutyrate-Derived Nitric Oxide Donor Induces Pancreatic Cancer Cell Death Accompanied by Impairment of Autophagy-Related Pathways and HIF-1&lt;i&gt;α&lt;/i&gt; Reductionhttps://www.pharmaradar360.com/article/preventive-effects-of-non-sedating-and-sedating-histamine-h-lt-sub-gt-1-lt-sub-g-da58c9a8e8c6b686Pharma Surgeen2026-07-24T00:00:00.000ZPreventive Effects of Non-sedating and Sedating Histamine H&lt;sub&gt;1&lt;/sub&gt; Receptor Antagonists Premedication for Subcutaneous Daratumumab-Associated Infusion-Related Reactions: A Prospective Observational Studyhttps://www.pharmaradar360.com/article/prenatal-care-for-disorders-differences-of-sex-development-10-years-look-back-in-714592a7be517c25Pharma Surgeen2026-07-24T00:00:00.000ZPrenatal care for Disorders/Differences of Sex Development: 10-years look back in an expert-centerhttps://www.pharmaradar360.com/article/low-versus-high-concentration-iodine-contrast-media-for-coronary-computed-tomogr-afb73e370e852fb1Pharma Surgeen2026-07-24T00:00:00.000ZLow- versus high-concentration iodine contrast media for coronary computed tomography angiography and dynamic stress computed tomography perfusion: a study protocol for a prospective randomized trial